ALFA Finder| Revenue growth | FY26 13.5% YoY; Q4 14.6% YoY. |
|---|---|
| Margins | FY26 EBITDA margin at 20.4%; guided 20-21% for FY27. |
| Demand visibility | Strong traction in chronic segments and international markets. |
| Management confidence | High; citing landmark year and successful new launches. |
Growth
Q4 revenue grew 14.6% YoY to INR 36,033m. FY26 revenue at INR 147,123m (up 13.5%) with 20.4% EBITDA margins.
Outlook
Targets 100-150 bps outperformance over Indian Pharma Market growth. FY27 EBITDA margins guided between 20-21%.
Risks
Geopolitical instability, increased logistics costs, and pricing pressure on APIs and packaging materials.
Earnings Call filed with BSE, NSE: ALKEM. Summary written with AI assistance from the document.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,114.00
- Market cap
- ₹61,146 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.6×Sector 43.7×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹4,520 Cr (+13.8%) and EBITDA margin 22.5%, but PAT fell 11.7%. US constant-currency sales contracted 3% on price erosion.
Alkem Laboratories Results Update
Alkem posted Q2FY27 revenue of ₹4,552 Cr, up 14% YoY, with 22.5% EBITDA margin. Net profit fell 11.7% to ₹675 Cr on higher R&D.
Alkem Laboratories Management Change
Alkem Laboratories appointed Mr. Gopal Kothari as CFO and Key Managerial Personnel effective 2 December 2026. The 24-year finance veteran is a CA and CS.
Alkem Laboratories Q2 FY27 Results: Net Profit ₹667.1 Cr, Down 14.4% YoY
Alkem Laboratories Ltd reported revenue from operations of ₹4,552 Cr (+13.8% YoY) and net profit of ₹667.1 Cr (-14.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹667.1 Cr · -14.4% YoY
Alkem Laboratories Merger & Restructuring Worth ₹9.56 Cr
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
- Value
- ₹9.56 Cr
Alkem Laboratories Board Meeting Date
Alkem Laboratories has scheduled its Board meeting for 12 Nov 2026 to consider Q2 and H1 FY27 unaudited results. No financial figures are disclosed in this advance notice.